Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin for Symptom Reduction in Multiple Myeloma Maintenance
NCT01269203Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2012
- Primary completion
- Oct 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
A Phase 2 trial of curcumin in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Planned start Oct 2012; status: withdrawn.
02
Drugs
curcumin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01269203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01269203.